Biocon is an innovation-led global biopharmaceuticals company committed to enhancing affordable access to complex therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases. Established in 1978, Biocon has developed and commercialised novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets. The company also produces generic formulations in the U.S., Europe, and key emerging markets while maintaining a robust pipeline of promising novel assets in immunotherapy under development.

Services include:
– Biologics
– Contract Development and Manufacturing (CDMO)
– Biosimilars
– Generic Formulations
– Complex Small Molecule APIs

Biocon continues to lead in the biopharmaceutical sector by focusing on innovation and affordability in healthcare. For more information, visit biocon.com.